var data={"title":"Nafcillin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nafcillin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6619?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nafcillin-drug-information\" class=\"drug drug_general\">see &quot;Nafcillin: Drug information&quot;</a> and <a href=\"topic.htm?path=nafcillin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nafcillin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048812\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Penicillin (Antistaphylococcal)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443894\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection (non-CNS):</b> (<i>Red Book </i>[AAP 2015]): IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight &lt;1 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &le;14 days: 25 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 15 to 28 days: 25 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight 1 to 2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &le;7 days: 25 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 8 to 28 days: 25 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight &gt;2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &le;7 days: 25 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 8 to 28 days: 25 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis:</b> IV (Tunkel 2004):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA 0 to 7 days: 75 mg/kg/day in divided doses every 8 to 12 hours for 14 to 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA 8 to 28 days: 100 to 150 mg/kg/day in divided doses every 6 to 8 hours for 14 to 21 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048804\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=nafcillin-drug-information\" class=\"drug drug_general\">see &quot;Nafcillin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP 2015]): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infections: IM, IV: 100 to 150 mg/kg/day in divided doses every 6 hours; maximum daily dose: 4 <b>g/day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infections: IM, IV: 150 to 200 mg/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 12 <b>g/day </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment</b> (AHA [Baltimore 2015]): Children and Adolescents: IV: 200 mg/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 12 <b>g</b>/<b>day</b>; treat for at least 4 weeks; longer durations may be necessary; may use in combination with gentamicin for some resistant organisms (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis:</b> Infants, Children, and Adolescents: IV: 200 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g/day</b> (Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue infections</b> (IDSA [Stevens 2014]): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA): IV: 100 to 150 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g</b>/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Necrotizing infection due to MSSA: IV: 200 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g</b>/<b>day;</b> continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Streptococcal skin infections: Infants, Children, and Adolescents: IV: 200 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g</b>/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment: Methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Native valve: IV: 12 <b>g</b>/day in 4 or 6 divided doses (ie, 2,000 mg every 4 hours or 3,000 mg every 6 hours) for 6 weeks. <b>Note:</b> Dosing intended for <i><b>complicated </b></i>right-sided infective endocarditis (IE) or left-sided IE. For <i><b>uncomplicated</b></i>right-sided IE, 2 weeks of therapy may be adequate (AHA [Baddour 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prosthetic valve: IV: 12 <b>g</b>/day in 6 divided doses (ie, 2,000 mg every 4 hours) for &ge;6 weeks (use with rifampin for entire course and gentamicin for first 2 weeks) (AHA [Baddour 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue infections</b> (IDSA [Stevens 2014]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA): IV: 1,000 to 2,000 mg every 4 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Necrotizing infection due to (MSSA): IV: 1,000 to 2,000 mg every 4 hours; continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours</p>\n    <p style=\"text-indent:-4em;margin-left:8em;\">Streptococcal infections: IV: 1,000 to 2,000 mg every 4 to 6 hours for 7 days, depending on clinical response (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> No dosage adjustment is necessary unless renal impairment is in the setting of concomitant hepatic impairment then use with caution; specific adjustment for combined renal and hepatic impairment is not provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD) (Aronoff 2007; Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment may be necessary particularly in the setting of concomitant renal impairment; nafcillin primarily undergoes hepatic metabolism. In patients with both hepatic and renal impairment, monitoring of serum drug concentrations and modification of dosage may be necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199154\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/50 mL (50 mL); 2 g/100 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199138\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50470565\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=nafcillin-drug-information\" class=\"drug drug_general\">see &quot;Nafcillin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nafcillin lyophilized powder contains sodium approximately 66 mg [2.9 mEq] per gram of nafcillin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nafcillin in Dextrose (iso-osmotic) contains sodium 76.6 mg [3.33 mEq] per gram of nafcillin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048816\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Administer reconstituted solution as deep intragluteal injection; rotate injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Direct IV injection: Further dilute, and administer over 5 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent IV infusion: Infuse over 30 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); remove needle/cannula; apply dry cold compresses (Hurst 2004); elevate extremity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199171\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Premixed infusions: Store in a freezer at  -20&deg;C (-4&deg;F). Thaw at room temperature or under refrigeration only. Thawed bags are stable for 21 days under refrigeration or 72 hours at room temperature. Do not refreeze.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Vials: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Reconstituted parenteral solution is stable for 3 days at room temperature and 7 days when refrigerated. For IV infusion in NS or D<sub>5</sub>W, solution is stable for 24 hours at room temperature and 7 days when refrigerated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solutions for ambulatory IV infusion reservoirs (eg, &gt;24-hour supply) may be subject to inadvertent exposure to temperatures higher than recommended due to heat radiation from patient's skin; lower concentrations of preparation may be needed to prevent precipitation of solution in some circumstances (Chan 2005). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048815\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of bacterial infections such as osteomyelitis, septicemia, endocarditis, and CNS infections due to susceptible penicillinase-producing strains of <i>Staphylococcus</i> [FDA approved in pediatric patients (IM) and adults (IM and IV)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199203\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Neurotoxicity (high doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin necrosis (with sloughing; subcutaneous extravasation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: <i>Clostridium difficile</i> associated diarrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, bone marrow depression, neutropenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, delayed hypersensitivity, immediate hypersensitivity, serum sickness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Inflammation at injection site, injection site phlebitis, local skin exfoliation (at injection site), pain at injection site, swelling at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Cholestatic hepatitis, diarrhea, fever, hypokalemia, increased serum ALT, increased serum AST, increased serum bilirubin, interstitial nephritis, lupus erythematosus (drug-induced), nausea, pruritus, renal tubular disease, skin rash (including bullous skin eruptions), vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199161\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to nafcillin, other penicillins, or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for beta-lactams (eg, penicillins and cephalosporins) is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199142\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity or a history of sensitivity to multiple allergens. Use with caution in patients with a history of significant allergies and/or asthma; discontinue treatment and institute appropriate therapy if an allergic reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; avoid extravasation of IV infusions; ensure proper catheter or needle position prior to and during infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Elevation of liver transaminases and/or cholestasis may occur, specifically with high doses. Reevaluate use in patients who develop worsening hepatic function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxic effects: Large IV or intraventricular doses have been associated with neurotoxicity; use caution, especially in patients with concomitant renal and hepatic dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: May contain a significant amount of sodium; use with caution in patients with heart failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic/renal impairment: Use with caution in patients with concomitant hepatic and renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use with caution in pediatric patients; elimination of drug may be decreased.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26017904\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In a study of pediatric patients (5 to 19 years) receiving outpatient nafcillin for &gt;3 weeks, significantly less rash was reported in the nafcillin group (10.3%) compared to oxacillin group (31.7%) (Maraqa, 2002). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199195\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Induces</b> CYP3A4 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199147\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12626&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bedaquiline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.  Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and impair its efficacy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobimetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Nafcillin may increase the metabolism of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inducers): CYP3A4 Inducers (Moderate) may decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daclatasvir.  Management: Increase the daclatasvir dose to 90 mg once daily if used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasabuvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflazacort: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elbasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elbasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estriol (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Estriol (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estriol (Topical): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Estriol (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Nafcillin may increase the metabolism of Estrogen Derivatives (Contraceptive).  Management: Use of an alternative, nonhormonal form of contraception during nafcillin therapy is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Grazoprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of GuanFACINE.  Management: Increase the guanfacine dose by up to double when initiating concomitant therapy with moderate CYP3A4 inducers. Increase guanfacine dose gradually over 1-2 weeks if moderate CYP3A4 inducer therapy is just beginning.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrutinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lurasidone.  Management: Monitor for decreased lurasidone effects if combined with moderate CYP3A4 inducers and consider increasing the lurasidone dose if coadministered with a moderate CYP3A4 inducer for 7 or more days.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirodenafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: Nafcillin may decrease the serum concentration of NIFEdipine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nisoldipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palbociclib.  Management: The US label does not provide specific recommendations concerning use with moderate CYP3A4 inducers, but the Canadian label recommends avoiding use of moderate CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Perampanel.  Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used concurrently with moderate and strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rolapitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rolapitant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sonidegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Nafcillin may diminish the anticoagulant effect of Vitamin K Antagonists.  Management: Consider choosing an alternative antibiotic. Monitor for decreased therapeutic effects and need for dose adjustments of oral anticoagulants if nafcillin is initiated/dose increased, or increased effects if nafcillin is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199150\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5720663\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Information specific to nafcillin use in pregnancy is limited. Maternal use of penicillins has generally not resulted in an increased risk of birth defects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048811\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Baseline and periodic CBC with differential, urinalysis, BUN, serum creatinine, AST, and ALT; initial culture and susceptibility test; observe for signs and symptoms of anaphylaxis during first dose and IV site for extravasation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199141\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with bacterial cell wall synthesis during active multiplication, causing cell wall destruction and resultant bactericidal activity against susceptible bacteria; resistant to inactivation by staphylococcal penicillinase  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199160\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely distributed; CSF penetration is poor but enhanced by meningeal inflammation  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub>: Neonates: 0.24 to 0.53 L/kg; Children: 0.85 to 0.91 L/kg; Adults: 0.57 to 1.55 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~90%; primarily to albumin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Primarily hepatic; undergoes enterohepatic recirculation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates &lt;3 weeks: 2.2 to 5.5 hours; 4 to 9 weeks: 1.2 to 2.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children 1 month to 14 years: 0.75 to 1.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Normal renal/hepatic function: 33 to 61 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: 30 to 60 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily feces; urine (~30% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323444\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nafcillin Sodium in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (50 mL): $17.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/100 mL (100 mL): $24.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Nafcillin Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $13.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $26.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $169.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Nafcillin Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $17.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $33.99</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/7396459/pubmed\" target=\"_blank\" id=\"7396459\">7396459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR , Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. <i>Circulation</i>. 2015;132(15):1435-1486.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Banner W Jr, Gooch WM 3d, Burckart G, et al, &quot;Pharmacokinetics of Nafcillin in Infants With Low Birth Weights,&quot; <i>Antimicrob Agents Chemother</i>, 1980, 17(4):691-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/7396459/pubmed\" target=\"_blank\" id=\"7396459\">7396459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chan V, &quot;Influence of Temperature and Drug Concentration on Nafcillin Precipitation,&quot; <i>Am J Health Syst Pharm</i>, 2005, 62(13):1347-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/15972371/pubmed\" target=\"_blank\" id=\"15972371\">15972371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, and Dager WE, &quot;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&quot; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/10318297 /pubmed\" target=\"_blank\" id=\"10318297 \">10318297 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maraqa NF, Gomez MM, Rathore MH, et al, &quot;Higher Occurrence of Hepatotoxicity and Rash in Patients Treated With Oxacillin, Compared With Those Treated With Nafcillin and Other Commonly Used Antimicrobials,&quot; <i>Clin Infect Dis</i>, 2002, 34(1):50-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/11731945/pubmed\" target=\"_blank\" id=\"11731945\">11731945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nafcillin [prescribing information]. Princeton, NJ: Sandoz Inc; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nafcillin [prescribing information]. Schaumberg, IL: Sagent Pharmaceuticals, Inc; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &quot;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2013, 56(1):e1-e25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson DC, Cookson TL, and Grisafe JA, &quot;Concentration Guidelines for Parenteral Antibiotics in Fluid-Restricted Patients,&quot; <i>Drug Intell Clin Pharm</i>, 1987, 21(12):985-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/3428165/pubmed\" target=\"_blank\" id=\"3428165\">3428165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i> . 2014;59(2):e10-e52. doi: 10.1093/cid/ciu444.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/24973422/pubmed\" target=\"_blank\" id=\"24973422\">24973422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &quot;Practice Guidelines for the Management of Bacterial Meningitis,&quot; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE, Dungy CL, and Greene CR, &quot;Nafcillin Extravasation Injury: Use of Hyaluronidase as an Antidote,&quot; <i>Am J Dis Child</i>, 1981, 135(12):1113-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/7315807/pubmed\" target=\"_blank\" id=\"7315807\">7315807</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12626 Version 173.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048812\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443894\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048804\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F199154\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F199138\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F50470565\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048816\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F199171\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048815\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F199203\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F199161\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F199142\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26017904\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F199195\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F199147\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F199150\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5720663\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048811\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F199141\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F199160\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323444\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12626|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nafcillin-drug-information\" class=\"drug drug_general\">Nafcillin: Drug information</a></li><li><a href=\"topic.htm?path=nafcillin-patient-drug-information\" class=\"drug drug_patient\">Nafcillin: Patient drug information</a></li></ul></div></div>","javascript":null}